# Semaglutide in Treatment of Obesity

> **NCT06604624** · PHASE3 · COMPLETED · sponsor: **CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.** · enrollment: 462 (actual)

## Conditions studied

- Weight Management

## Interventions

- **DRUG:** HD1916
- **DRUG:** semaglutide

## Key facts

- **NCT ID:** NCT06604624
- **Lead sponsor:** CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-20
- **Primary completion:** 2025-08-27
- **Final completion:** 2025-09-24
- **Target enrollment:** 462 (ACTUAL)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06604624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06604624, "Semaglutide in Treatment of Obesity". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06604624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*